跳转至内容
Merck

SML0778

Sigma-Aldrich

UNC1999

≥98% (HPLC)

别名:

1-Isopropyl-6-(6-(4-isopropylpiperazin-1-yl)pyridin-3-yl)-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-1H-indazole-4-carboxamide

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C33H43N7O2
分子量:
569.74
MDL號碼:
分類程式碼代碼:
41121800
PubChem物質ID:
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 15 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

CC(C)N1CCN(C2=NC=C(C3=CC4=C(C=NN4C(C)C)C(C(NCC5=C(CCC)C=C(C)NC5=O)=O)=C3)C=C2)CC1

InChI

1S/C33H43N7O2/c1-7-8-24-15-23(6)37-33(42)28(24)19-35-32(41)27-16-26(17-30-29(27)20-36-40(30)22(4)5)25-9-10-31(34-18-25)39-13-11-38(12-14-39)21(2)3/h9-10,15-18,20-22H,7-8,11-14,19H2,1-6H3,(H,35,41)(H,37,42)

InChI 密鑰

DPJNKUOXBZSZAI-UHFFFAOYSA-N

生化/生理作用

多梳抑制络合物 2 (PRC2)通过组蛋白 H3 在赖氨酸 27 (H3K27) 上的甲基化来抑制基因表达,其中包含作为其的催化亚基的EZH1 或 EZH2 ,EZH1 在分裂细胞和非分裂细胞中均有发现,而 EZH2 仅在活跃分裂细胞中有发现。UNC1999 是一种口服的 EZH2 和 EZH1 赖氨酸甲基转移酶的选择性抑制剂,同时IC 50 < 10 nM (EZH2)和 IC 50< 45 nM (EZH1)。UNC1999 强效抑制野生型和突变型 Y641N EZH2 甲基转移酶活性的能力相差不到 5 倍,并选择性杀死携带 Y641 点突变的弥散性大 B 细胞淋巴瘤(DLBCL)细胞。它对 EZH2 和 EZH1 的选择性高于其他 15 种赖氨酸、精氨酸和 DNA 甲基转移酶。UNC1999 与辅因子 S-腺苷甲硫氨酸(SAM)竞争,但不与肽底物竞争。因为它同时抑制 EZH2 和 EZH1,在 PRC2–EZH2 和 PRC2–EZH1 都促进 H3K27 甲基化的疾病环境中,UNC1999 比 EZH2 选择性抑制剂有潜在的优势。

有关表征的完整详细信息,请访问结构基因组学联盟(SGC)网站上的 UNC1999 探针摘要

UNC2400 是活性探针 UNC1999 的阴性对照物。要从SGC 获取阴性对照样品, 单击此处

想要了解用于表观遗传靶标的其他SGC化学探针,请访问sigma.com/sgc

特點和優勢

UNC1999是一种表观遗传化学探针,是我们与Structural Genomics Consortium (SGC) 合作研发的。想要了解更多信息并查看其他SGC表观遗传探针,请访问sigma.com/SGC
这种化合物是基因调控研究的特色产物。点击此处查看更多特色基因调控产物。登录sigma.com/discover-bsm可了解更多关于其他研究领域中关于生物活性小分子的消息。

其他說明

在化学探针门户网站上,已有专家审查和推荐了UNC1999。欲了解更多信息,请访问化学探针门户网站上的 UNC1999 探针摘要

相關產品

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Peter E Feist et al.
Analytical chemistry, 89(5), 2773-2781 (2017-02-15)
Multicellular tumor spheroids (MCTS) are valuable in vitro tumor models frequently used to evaluate the penetration and efficacy of therapeutics. In this study, we evaluated potential differences in epigenetic markers, i.e., histone post-translational modifications (PTMs), in the layers of the
Chen Hou et al.
Frontiers in genetics, 13, 1013475-1013475 (2022-10-25)
Although gene mutations and aberrant chromosomes are associated with the pathogenesis and prognosis of uveal melanoma (UM), potential therapeutic targets still need to be explored. We aim to determine the predictive value and potential therapeutic target of EZH2 in uveal
Kyunghwan Kim et al.
Epigenetics & chromatin, 11(1), 23-23 (2018-05-29)
MMP-9 plays a direct role in the activation of pro-osteoclastogenic genes by cleaving histone H3N-terminal tail (H3NT) and altering chromatin architecture. Although H3 acetylation at K18 has been shown to stimulate MMP-9 enzymatic activity toward H3NT, nothing is known about
Christiaan J Stavast et al.
Leukemia (2021-11-07)
MIR139 is a tumor suppressor and is commonly silenced in acute myeloid leukemia (AML). However, the tumor-suppressing activities of miR-139 and molecular mechanisms of MIR139-silencing remain largely unknown. Here, we studied the poorly prognostic MLL-AF9 fusion protein-expressing AML. We show
Iva A Tchasovnikarova et al.
Molecular cell, 82(2), 479-491 (2021-12-29)
Genetically encoded biosensors are powerful tools to monitor cellular behavior, but the difficulty in generating appropriate reporters for chromatin factors hampers our ability to dissect epigenetic pathways. Here, we present TRACE (transgene reporters across chromatin environments), a high-throughput, genome-wide technique

商品

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门